CCXI ChemoCentryx Inc

Price (delayed)

$62.00

Market cap

$4.29B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.65

Enterprise value

$4.29B

Sector: Healthcare
Industry: Biotechnology

Highlights

The quick ratio rose by 12% since the previous quarter
ChemoCentryx's gross profit has soared by 99% YoY but it has decreased by 7% from the previous quarter
The revenue has soared by 99% YoY but it fell by 7% QoQ
The debt has soared by 197% YoY and by 14% QoQ
The company's equity fell by 3.9% QoQ

Key stats

What are the main financial stats of CCXI
Market
Shares outstanding
69.21M
Market cap
$4.29B
Enterprise value
$4.29B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
10.55
Price to sales (P/S)
60.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
60.83
Earnings
Revenue
$70.58M
EBIT
-$38.55M
EBITDA
-$36.32M
Free cash flow
-$88.61M
Per share
EPS
-$0.65
Free cash flow per share
-$1.29
Book value per share
$5.88
Revenue per share
$1.02
TBVPS
$7.73
Balance sheet
Total assets
$533.04M
Total liabilities
$128.22M
Debt
$58.76M
Equity
$404.82M
Working capital
$427.58M
Liquidity
Debt to equity
0.15
Current ratio
10.12
Quick ratio
10.06
Net debt/EBITDA
-0.07
Margins
EBITDA margin
-51.5%
Gross margin
100%
Net margin
-58.1%
Operating margin
-59.1%
Efficiency
Return on assets
-11.1%
Return on equity
-17.2%
Return on invested capital
-16.6%
Return on capital employed
-7.9%
Return on sales
-54.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CCXI stock price

How has the ChemoCentryx stock price performed over time
Intraday
-2.19%
1 week
-1.24%
1 month
-4.85%
1 year
64.67%
YTD
0.13%
QTD
0.13%

Financial performance

How have ChemoCentryx's revenue and profit performed over time
Revenue
$70.58M
Gross profit
$70.58M
Operating income
-$41.72M
Net income
-$41.01M
Gross margin
100%
Net margin
-58.1%
ChemoCentryx's gross profit has soared by 99% YoY but it has decreased by 7% from the previous quarter
The revenue has soared by 99% YoY but it fell by 7% QoQ
The company's operating margin has surged by 61% YoY but it fell by 43% QoQ
The net margin has soared by 59% YoY but it is down by 48% QoQ

Growth

What is ChemoCentryx's growth rate over time

Valuation

What is ChemoCentryx stock price valuation
P/E
N/A
P/B
10.55
P/S
60.54
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
60.83
The EPS has grown by 29% YoY but it has contracted by 25% from the previous quarter
CCXI's P/B is 55% below its last 4 quarters average of 23.5 and 29% below its 5-year quarterly average of 14.8
The company's equity fell by 3.9% QoQ
The price to sales (P/S) is 114% higher than the 5-year quarterly average of 28.3 and 2.4% higher than the last 4 quarters average of 59.1
The revenue has soared by 99% YoY but it fell by 7% QoQ

Efficiency

How efficient is ChemoCentryx business performance
The company's return on equity has surged by 81% YoY and by 12% QoQ
The ROS has soared by 60% YoY but it has plunged by 51% from the previous quarter
The return on invested capital has surged by 56% year-on-year and by 13% since the previous quarter
The ROA has soared by 53% YoY but it has contracted by 8% from the previous quarter

Dividends

What is CCXI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CCXI.

Financial health

How did ChemoCentryx financials performed over time
The company's total liabilities fell by 15% YoY but it rose by 6% QoQ
The debt is 85% lower than the equity
The debt has soared by 197% YoY and by 14% QoQ
The debt to equity has plunged by 53% YoY but it has increased by 25% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.